Immunic's Vidofludimus Calcium Shows Sustained Disability Outcome Trends in Phase 2 MS Extension Study

• Immunic reported sustained disability outcome trends with continued vidofludimus calcium treatment in the Phase 2 CALLIPER open-label extension for progressive multiple sclerosis.
• Discontinuations totaled 6.5% through January 27, 2026; safety and tolerability appeared consistent with the double-blind period.
• A post-hoc analysis found treated patients 1.5 times more likely than placebo recipients to achieve better disability outcomes (p=0.042).
• Exploratory analyses showed reduced EBV-specific T-cell receptor signatures versus placebo (p=0.0004); reductions were associated with improved cognitive processing scores.
• Preclinical findings suggested Nurr1-dependent neuronal survival beyond DHODH inhibition, with reduced disease severity in mouse models of multiple sclerosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2419140_en) on October 21, 2026, and is solely responsible for the information contained therein.